Small scale bioreactors are miniature-scale instruments used for cultivating microbial or cell cultures in a limited quantity of growth medium, generally for research purposes. These bioreactors provide various advantages over shake flasks such as better mixing, oxygen transfer, nutrient addition, oxygen level maintenance, temperature control, and pH control. Given the capability to culture cells for vaccines and therapeutics production at small scale under closely monitored and controlled conditions, small scale bioreactors find widespread application in the pharmaceutical industry.
The global Small Scale Bioreactors Market is estimated to be valued at US$ 188.5 million in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of single use bioreactors in the pharmaceutical industry has been a key growth driver for the small scale bioreactors market. Single-use bioreactors are meant for carrying out regulated processes on a small scale with small volume of media. They eliminate concerns related to cleaning validation and sterility assurance which are crucial requirements for the pharmaceutical industry. Single-use bioreactors therefore provide faster development and manufacturing cycles along with reduced facility footprints making them an ideal solution for R&D and clinical studies in the biopharma industry. The benefits of single-use bioreactors have led to their widespread adoption especially for manufacture of vaccines and cell and gene therapies.
SWOT Analysis
Strength: Small Scale Bioreactors Scope have high flexibility and can be easily sterilized for various applications like research, process development and small production batches. They offer scalability and reduced operational costs.
Weakness: Initial investment cost for small scale bioreactors may be higher as compared to benchtop models. Consistency in performance needs to be improved for some types of bioreactors.
Opportunity: Growing demand for monoclonal antibodies, vaccines and other biologics will drive the adoption of small scale bioreactors in R&D activities. Emerging markets offer huge potential for small scale bioreactors market.
Threats: Shift towards large scale production once research and development activities progress poses a threat. Intense competition from major players may impact profit margins.
Key Takeaways
The global small scale bioreactors market is expected to witness high growth over the forecast period of 2022-2028.
Regional analysis: North America region currently dominates the small scale bioreactors market owing to high R&D investments in biopharmaceutical industry. Asia Pacific is expected to grow at the fastest rate due to increasing biologics production in China, India and other emerging countries.
Key players: Key players operating in the small scale bioreactors market are Thermo Fisher Scientific, Merck KGaA, Sartorius Stedim Biotech S.A., GE Healthcare, Danaher (Pall Corporation), Eppendorf AG, Praj Hipurity Systems, Pierre Guerin, ZETA Holding SA, and Applikon Biotechnology BV.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.